Hatime Arzu Yasar

16PUBLICATIONS
110CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCellular immunologyMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jul 15, 2026
Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study.

|May 04, 2026
Clinicopathological Predictors of Pathological Complete Response in HER2-Positive Breast Cancer Treated with Pertuzumab-Based Neoadjuvant Therapy: A Multicenter Real-World Study.

|Mar 26, 2026
Resectable Stage Early-Onset Biliary Tract Cancer: Survival and Prognostic Scoring (EOB-RS and EOB-OS) in Turkish Patients (TOG/GI-SAFRADJU-2502-EO).

Erman Akkus, Mehmet Kayaalp, Müzeyyen Aslı Ergözoğlu

|Jan 09, 2026
Chemotherapy tolerance and continuity are prognostic for overall survival in patients with localized and advanced biliary tract cancer.

Erman Akkuş, Pınar Kubilay Tolunay, Elif Berna Köksoy

|Sep 27, 2025
Confirmation of Large Language Models in Head and Neck Cancer Staging.

Mehmet Kayaalp, Hatice Bölek, Hatime Arzu Yaşar

|Jun 26, 2025
Induction or Adjuvant Chemotherapy in Patients with Locally Advanced Nasopharyngeal Cancer Receiving Chemoradiotherapy? A Turkish Oncology Group Study.

Serhat Sekmek, Aysel Oguz, Melek Karakurt Eryilmaz

Pageof 3

Frequent Collaborators

7 joint publications

Yüksel Ürün

5 joint publications

Ali Alkan

3 joint publications

Mehmet Kayaalp

3 joint publications

Ertugrul Bayram